This narrative review explores how the intestinal microbiome interacts with SARS-CoV-2 infection. The authors discuss how the virus might cause intestinal dysbiosis and modify immune signaling. They also note that the microbiota-gut-brain axis could affect neuropsychiatric and metabolic complications. Because the study is a narrative review, it summarizes existing ideas rather than testing new treatments on people. No specific patient groups or sample sizes were reported in this source. The authors did not find safety data or adverse events because this was not a clinical trial. The main reason to be careful is that these are theoretical connections, not proven causes. Readers should understand that integrating microbiome research into pandemic preparedness is a suggestion for future planning. This approach fits within a One Health framework that connects human, animal, and environmental health. More research is needed before any specific advice can be given to patients.
Narrative review on COVID-19 and gut microbiome disruption and immune effectsMicrobiome disruption may link SARS-CoV-2 to long-term health issues
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider the observational link between COVID-19, gut dysbiosis, and immune changes for pandemic planning.
This is a narrative review on COVID-19 and the intestinal microbiome. The scope covers how SARS-CoV-2 infection relates to microbiome disruption, potential roles for probiotics, prebiotics, and fecal microbiota transplantation, and implications for immune and neuropsychiatric outcomes.
The authors synthesize that SARS-CoV-2 infection can induce intestinal dysbiosis and modify immune signaling. They note that neuropsychiatric and metabolic complications may be affected by the microbiota-gut-brain axis. No pooled effect sizes or quantitative results are reported.
Key limitations noted include the lack of reported effect sizes, absolute numbers, p-values, or confidence intervals for the synthesized findings. The review does not report a defined study population, sample size, or follow-up period.
Practice relevance is framed as integrating microbiome research into pandemic preparedness through a One Health approach. The authors do not report safety data or causality assessments, and the evidence remains observational and preliminary.
What this means for you:
This review suggests gut bacteria changes may link to COVID-19 complications, but more research is needed. More on COVID
Organizational resilience and psychological support are key to improving ICU nurse teamwork during pandemics
Teamwork challenges and strengths for ICU nurses in COVID-19
This meta-synthesis of 48 qualitative studies examines the challenges and coping strategies of ICU nurses regarding team collaboration durin…
A review of 48 studies reveals what helped and hurt teamwork for ICU nurses during COVID-19.
CT-assessed sarcopenia combined with inflammatory markers predicts higher mortality in critically ill and COVID-19 patients
Low muscle mass and inflammation linked to higher COVID-19 mortality
This meta-analysis of 12,347 patients evaluated the prognostic value of CT-assessed sarcopenia combined with laboratory inflammatory markers…
A large review of patient data shows that low muscle mass combined with high inflammation markers may predict worse outcomes for severe COVI…
Favipiravir co-administration with lopinavir-ritonavir increased favipiravir clearance by twofold in COVID-19 patients
Trial shows favipiravir and lopinavir-ritonavir do not stop COVID-19
This Phase 2a randomized, double-blind, 2x2 factorial placebo-controlled trial evaluated favipiravir and lopinavir-ritonavir in patients wit…
A new trial reveals that combining favipiravir with lopinavir-ritonavir did not show antiviral activity against the virus in patients with C…
Ensitrelvir improves viral clearance and reduces viral RNA in patients with mild-to-moderate COVID-19
Ensitrelvir helps clear the virus in mild to moderate COVID-19
This meta-analysis of 2,890 patients found that Ensitrelvir (125 mg or 250 mg) significantly improved viral clearance and reduced viral RNA …
New data shows that Ensitrelvir can help patients with mild to moderate COVID-19 clear the virus from their systems more quickly.
View Original Abstract ↓
Emerging infectious diseases, particularly zoonotic ones, remain major global health concerns. The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), highlights the interconnectedness of human, animal, and environmental health within the One Health framework. The intestinal microbiome plays a central role in host immunity and systemic homeostasis, and its disruption has been linked to altered disease severity and recovery patterns in COVID-19. Evidence suggests that SARS-CoV-2 infection induces intestinal dysbiosis, modifies immune signaling, and affects the microbiota-gut-brain axis (MGBA), contributing to neuropsychiatric and metabolic complications. This review synthesizes current findings on the intestinal microbiome’s role in COVID-19 pathophysiology and recovery, explores emerging therapeutic strategies including probiotics, prebiotics, and fecal microbiota transplantation, and emphasizes the importance of integrating microbiome research into pandemic preparedness through a One Health approach.
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
FDA Approves Fetroja (cefiderocol) for Complicated UTIs and Hospital-Acquired Pneumonia
FDA approves new antibiotic Fetroja for serious bacterial infections
The FDA approved Fetroja (cefiderocol) for complicated urinary tract infections (cUTI) including pyelonephritis, and hospital-acquired bacte…
The FDA approved Fetroja (cefiderocol) to treat complicated urinary tract infections and certain pneumonia types in adults. It targets hard-…
5-day oral antibiotics as effective as 10-day course for pediatric GAS pharyngitis
Shorter antibiotic courses may treat strep throat in children
A systematic review and dose-response meta-analysis of 22,636 children found little to no difference in clinical outcomes between 3, 5, and …
A review of over 20,000 cases suggests a 5-day course of antibiotics is as effective as 10 days for treating strep throat in children.
Cefdinir and cefprozil show superior eradication rates compared to penicillin V for Group A streptococcal pharyngitis
Certain antibiotics work better than others for strep throat
This network meta-analysis of 64 RCTs involving 23,287 participants evaluated 24 antibiotics for Group A streptococcal (GAS) pharyngitis. Th…
New data shows that while some antibiotics effectively clear strep throat, azithromycin performs poorly and carries more risks.
Vonoprazan-amoxicillin dual therapy is a safe alternative to bismuth-containing quadruple therapy for H. pylori
New vonoprazan treatments show promise for clearing H. pylori infection
This multicenter randomized controlled trial of 579 H. pylori-positive patients found that vonoprazan-amoxicillin (VA) dual therapy demonstr…
Two new simplified drug combinations could offer a simpler way to clear H. pylori infections, especially for patients with certain allergies…
From Other Specialties
30% of pediatric patients with migraine report at least one adverse event during pharmacological prophylaxis
Trial Shows Specific Side Effects for Children with Migraine
This meta-analysis of 2742 patients evaluates the safety profile of various pharmacological migraine prophylaxis treatments in children and …
About 30% of children and adolescents taking migraine prevention medication report experiencing at least one side effect during treatment.
Dermatitis Herpetiformis prevalence in Celiac Disease patients is 6.8% with high heterogeneity
Celiac disease patients have higher risk of itchy skin condition
This meta-analysis of 73,905 patients with celiac disease found an overall pooled prevalence of dermatitis herpetiformis (DH) at 6.8%. While…
Nearly 7 percent of people with celiac disease also develop a painful, itchy skin condition called dermatitis herpetiformis.
Positive outcomes are independently associated with higher journal impact factors in gynecologic oncology trials
Positive Trial Results Linked to Higher Journal Impact Factors
This meta-epidemiologic analysis of 36 phase III gynecologic oncology trials found that studies reporting positive outcomes were published i…
Trials with positive outcomes are more likely to be published in high-impact journals, which may affect how much attention negative results …
Mental Health Stigma Among Nursing Students Remains High
Nursing students still hold moderate to high mental health stigma
An integrative review of 25 studies finds moderate to high mental health stigma among nursing students, with multi-component interventions s…
A review of 25 studies finds nursing students have moderate to high stigma toward mental illness. Multi-component interventions show the mos…